Aurigene Oncology Limited, a subsidiary of Dr Reddy’s Laboratories Limited, is dedicated to developing innovative treatments for cancer and has released phase 1 findings for DRL-1801 in the SWASTH study - India's initial trial for a new CAR-T cell...
ModeX Therapeutics Inc, a biotechnology company under OPKO Health, Inc., reveals that it has received $35 million more in funding from BARDA, a branch of HHS responsible for Strategic Preparedness and Response in the US. The firm will start...
Boehringer Ingelheim, a biopharmaceutical company involved in human and animal health, revealed that the FDA has given Breakthrough Therapy status to survodutide (BI 456906), a dual glucagon/GLP-1 receptor agonist for treating adults with non...
.webp)
In pharmaceutical plant design, explosion-proof safety management is a critical factor for ensuring safe and efficient operations. Given that pharmaceutical production often involves large quantities of flammable and explosive chemicals.
Amneal Pharmaceuticals, a US company, announced plans to pour USD 200 million (around Rs 1,680 crore) into India for constructing two new manufacturing units in Ahmedabad within the next four to five years. The company announced plans for two new...
Nawaloka Hospitals PLC reaffirmed its dedication to providing top-notch patient-centered care by agreeing to a Memorandum of Understanding (MoU) with the National Insurance Trust Fund (NITF) to offer significant discounts to government employees...
GE Healthcare, a top international company in medical technology, pharmaceutical diagnostics, and digital solutions, has finished the first stage of testing for a unique MRI contrast agent made from manganese. According to an abstract presented at...
Exact Sciences Corp., a top supplier of cancer screening and diagnostic exams, disclosed that the Cologuard Plus test, the firm's advanced multitarget stool DNA test, was given the approval by the US Food and Drug Administration (FDA)...
AstraZeneca, a British company, has partnered exclusively with CSPC Pharmaceutical Group from China to further develop a new small molecule disruptor for Lipoprotein (a) (Lp(a)), which could provide extra benefits for dyslipidemia patients...
TiumBio Co., Ltd, a company specializing in biopharmaceuticals in the clinical development stage, revealed that the initial participant has been administered in the phase 2 clinical study of TU2218. TU2218 is a new oral inhibitor that targets both...
, CDSCO.jpg)
